Company Filing History:
Years Active: 2005-2006
Title: Inventor Spotlight: Zach Cheruvallath
Introduction
Zach Cheruvallath is a notable inventor based in San Diego, CA, with a significant contribution to the field of biochemistry and pharmaceuticals. With three patents to his name, Cheruvallath is recognized for his innovative work in developing compounds that target nuclear receptors, which play a crucial role in cellular communication and disease treatment.
Latest Patents
Cheruvallath's most recent patents include groundbreaking inventions related to FXR NR1H4 nuclear receptor binding compounds. The first patent outlines a series of compounds that bind to the NRH receptor, functioning as agonists, antagonists, or mixed agonists/antagonists. This invention not only highlights the structural formula of these compounds but also emphasizes their potential in treating various diseases and conditions through the binding of the nuclear receptor.
His second patent pertains to compounds that specifically target the NR1H4 nuclear receptor, acting as both agonists and antagonists. This invention further enhances the therapeutic applications of nuclear receptor binding, paving the way for new medicaments in modern medicine.
Career Highlights
Throughout his career, Zach Cheruvallath has worked with esteemed companies such as Phenex Pharmaceuticals AG, where he has likely contributed to the development of numerous pharmaceutical advancements. His expertise in receptor-binding compounds marks him as a key figure in the biopharmaceutical industry.
Collaborations
Cheruvallath has collaborated with professionals like Ulrike Bauer and Ulrich Deuschle, further strengthening the innovative research environment in which he operates. Such collaborations are essential for advancing complex projects and showcasing the combined expertise necessary for successful innovations.
Conclusion
Zach Cheruvallath exemplifies the spirit of innovation in the biotech field, with his pioneering patents serving to enhance our understanding of nuclear receptor binding and its implications for treating various medical conditions. His collaboration with leading professionals and impactful companies underscores the importance of teamwork in driving forward scientific discoveries that benefit society.